Mucosal-Associated Invariant T Cells as a Possible Target to Suppress Secondary Infections at COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Mucosal-associated invariant T-cells in pulmonary pathophysiology.Current opinion in pulmonary medicine · 2025
   Review
2. Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study.Frontiers in pharmacology · 2022
   Article
3. Coronavirus disease-2019 and the intestinal tract: An overview.World journal of gastroenterology · 2021
   Review
4. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.Microbial pathogenesis · 2021
   Review
5. Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19.Frontiers in immunology · 2021
   Article

Corrections and comments

• Comment on
  Co-infections: potentially lethal and unexplored in COVID-19.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as